Molecular diagnosis of entecavir resistance

Hepatitis Monthly

Volumn 10, Issue 1, 2010, Pages 42-47

  Sayan, Murat ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Chronic hepatitis B; Entecavir; Entecavir resistance; Molecular diagnosis; Nucleoside analogue

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; TELBIVUDINE;

AMINO ACID SUBSTITUTION; BACTERIAL GENE; CHRONIC HEPATITIS; CHRONIC PATIENT; CROSS RESISTANCE; DIAGNOSTIC PROCEDURE; DRUG MONITORING; GENOTYPE; HEALTH CARE UTILIZATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MOLECULAR CLONING; NONHUMAN; PREVALENCE; REFRACTORY PERIOD; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SEQUENCE ANALYSIS; STRUCTURAL GENE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS MUTATION;

EID: 77949693051     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227-42.
2. Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic hepatitis B. Future Microbiol. 2008;3:525-38.
3. Amini-Bavil-Olyaee S, Trautwein C, Tacke F. Relevance of hepatitis B virus genome variability in organ transplantation. Hepat Mon. 2007;7(1):35 - 41.
4. Harrison TJ. Hepatitis B virus: molecular virology and common mutants. Semin Liver Dis. 2006;26(2):87-96.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45(2):507-39.
6. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006;44(3):593-606.
7. Fung SK, Fontana RJ. Management of drug-resistant chronic hepatitis B. Clin Liver Dis. 2006;10(2):275-302, viii.
8. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat. 2006;13(7):427-34.
9. Dimou E, Papadimitropoulos V, Hadziyannis SJ. The role of entecavir in the treatment of chronic hepatitis B. Ther Clin Risk Manag. 2007;3(6):1077-86.
10. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001-10.
11. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology. 2009;49(1):72-9.
12. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48(9):3498-507.
13. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2008;28(2):167-77.
14. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503-14.
15. Tenney D, Pokornowski K, Rose R, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int. 2008;2(Suppl 2):S76-7.
16. Villet S, Pichoud C, Ollivet A, Villeneuve J, Trepo C, Zoulim F. Sequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virus. Hepatology. 2005;42(Suppl 1):581A.
17. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology. 2002;122(2):264-73.
18. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2(2):147-51.
19. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46(1):254-65.
20. Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y. Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol. 2008;6(3):268-74.
21. Jardi R, Rodriguez-Frias F, Schaper M, et al. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat. 2007;14(12):835-40.
22. Jardi R, Rodriguez-Frias F, Tabernero D, et al. Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy. J Clin Microbiol. 2009;47(2):485-8.
23. Kobashi H, Fujioka S, Kawaguchi M, et al. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int. 2009;3(2):403-10.
24. Sayan M, Akhan SC, Meric M. Naturally occurring aminoacid substitutions to nucleos(t)ide analogues in treatment naive Turkish patients with chronic hepatitis B. J Viral Hepat. 2010;17(1):23-7.
25. Sayan M, Hulagu S, Akhan SC, Senturk O, Meric M, Cekmen M. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients]. Mikrobiyol Bul. 2009;43(3):425-32.
26. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet. 1997;349(9044):20-2.
27. Schildgen O, Sirma H, Funk A, et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med. 2006;354(17): 1807-12.
28. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007;51(3):902-11.
29. Pei F, Ning JY, You JF, Yang JP, Zheng J. YMDD variants of HBV DNA polymerase gene: rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation. World J Gastroenterol. 2005;11(18):2714-9.
30. Sertoz RY, Erensoy S, Pas S, et al. Comparison of sequence analysis and INNO-LiPA HBV DR line probe assay in patients with chronic hepatitis B. J Chemother. 2005;17(5):514-20.
31. Yuen LK, Ayres A, Littlejohn M, et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res. 2007;75(1):64-74.
32. Niesters HG, Pas S, de Man RA. Detection of hepatitis B virus genotypes and mutants: current status. J Clin Virol. 2005;34 Suppl 1:S4-8.
33. Lok AS, Zoulim F, Locarnini S, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol. 2002;40(10):3729-34.
34. Valsamakis A. Molecular testing in the diagnosis and management of chronic hepatitis B. Clin Microbiol Rev. 2007;20(3):426-39, table of contents.
35. Karatayli E, Karayalcin S, Karaaslan H, et al. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir Ther. 2007;12(5):761-8.
36. Tran N, Berne R, Chann R, et al. European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes. J Clin Microbiol. 2006;44(8):2792-800.
37. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006;44(6):1656-65.
38. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46(3):531-8.
39. Bidgoli AS, Daryani NE, Motamedi M, Miri A, Poorsamimi P. Evaluation of possible risk factors of lamivudine resistance in chronic hepatitis b patients: a retrospective study in Iran. Hepat Mon. 2009;9(3):171-9.
40. Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2(1):8-16.